MapLight Therapeutics, Inc.
MPLT · XNASCIK 1770069fmd_1FTPJRPRVKYXQ425HSNBVH5F3VManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2024 to Jun 30, 2026, 10 periods
| Line item | FY2024 | FY2025 |
|---|---|---|
| Research and development | 69 | 138 |
| Total operating expenses | 83 | 169 |
| Operating income | (83) | (169) |
| Interest and investment income | 5 | 6 |
| Other non-operating income (expense) | 5 | 8 |
| Net income | (78) | (161) |